Clinical Research Directory

Inclusion Criteria: * Patients aged ≥ 18 years and ≤ 65 years. * Patient followed by a specialist in allergy and/or respiratory diseases working at one of the investigating sites in France. * Patient allergic to HDM and with a clinical history of HDM-allergic asthma. * Positive specific IgE (≥ 0.35 kUA/L, ImmunoCAP®) and positive skin prick test for Dermtophagoides pteronyssinus and/or Dermtophagoides farinae at screening. * Patients satisfying diagnostic criteria for severe asthma, according to GINA international guidelines. * A clinical history of asthma exacerbations in the past two years. * A history of at least 2 asthma exacerbations during the previous 12 months. * Uncontrolled asthma (ACT \<20/25) * Lung function measured by FEV1 ≥ 70% of predicted value or according to local requirements. * Patients with persistent severe asthma who meet the Marketing Authorization criteria for Tezspire® (Tezepelumab) and Acarizax® prescriptions. Exclusion Criteria: * Patients sensitized and regularly exposed to animal dander, molds, and/or cockroach or any another perennial allergen. * Patients treated with a monoclonal antibody for asthma within the previous 3 months or 5 half-lives. * Patients who have received Sublingual immunotherapy (SLIT) or Sub-Cutaneous Immunotherapy (SCIT) treatment with DermatophagoIdes pteronyssinus and/or Dermatophagoïdes farinae within the previous 5 years. * Patients received any education provided by a medical indoor environment counselor during the 12 months before the study, or and educational program is programmed during the study. * Patients with acute respiratory tract infections. * The patient who have performed any specific measure for mites' avoidance during the 12 months before the study or plan to implement such measures during the study. * Pregnant, breastfeeding or lactating women. * Patients with a history of tumor, autoimmune, or immune deficiency pathology. * Patients with hematological pathology (coagulation disorders, anemia) that could interfere with the blood test. * The patient reports any previous hypersensitivity reaction to the active substance or excipients present in Tezspire® or Acarizax®. * Patients unable to read and/or write French language. * Absence of signed consent. * Patients who are not beneficiaries of the French social security system. * Presence of any condition (physical, psychological or other) that might, in the investigator's opinion, hinder study performance. * The patient is unavailable or unwilling to participate in future visits or is unable to comply with trial protocol. * Women of childbearing potential and fertile men not using effective contraception. * The patient is participating in another study for asthma and/or allergy treatment. * Patients in an exclusion period determined by a previous study or is currently participating to any other allergy/asthma trial. * Patients under legal protection (guardianship or curatorship) * Patients with a business or personal relationship with trial staff or sponsor who is directly involved with the conduct of the trial.